The "Business" of Eradicating Disease
May 16, MIT
The MIT Biomedical Engineering Society hosted a debate between 6 thought leaders in Venture Capital, Public Policy, Intellectual Property, Diagnostic Devices, Global Health Relief, and Pharmaceuticals.
It was a lively discussion, extended at LTDC Conferences and Lectures if you are interested.
Exciting points and questions raised were:
- Addressing the co-dependency of Medical Delivery, Affordability, and Drug Discovery.
- Common myths about Big Pharma (nicer than they are given credit for)
- The unsustainability of American health product subsidies (we pay more) towards developing countries (they don't pay their share).
- A $100 billion prize for an Alzheimers blockbuster in exchange for licensing?
- The conversion of fractured markets to rational markets. Where is the tipping point? Can you find it? Can you drive it?
- The coming age of real and profitable market opportunities in the developing world health markets.
- Redefining markets so patent holders can use them as a viable tool, not as a punching bag
- Finding the right technology, but more importantly---timing it
- If the Global Sales Opp/Product Dev <>
- Doctors in global public health taking on implementation science: The need to re-engineer the "global health product" from its failed business practices in global
- Encouraging single-use products aimed at developing world, not just trickle down dual-use technologies: Where's the funding? Where's the vision?
More at MIT